| Literature DB >> 12400781 |
H Edward Garrett1, Kenneth Groshart, Denise Duvall-Seaman, Deena Combs, Rita Suggs.
Abstract
Humoral vascular rejection is a B cell-mediated production of immunoglobulin G antibody against the transplanted organ. Available treatments of vascular rejection offer limited success, and chronic manifestations of vascular rejection require retransplantation. On the basis of the mechanism of action of rituximab, we successfully treated 1 patient with vascular rejection refractory to plasmapheresis with this drug without major toxicity.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12400781 DOI： 10.1016/s0003-4975(02)03824-9
Source DB: PubMed Journal: Ann Thorac Surg ISSN： 0003-4975 Impact factor: 4.330